Mike Wilson: Outside the Consensus
We forecast a shorter and hotter business cycle than the consensus estimates, suggesting a move to mid-cycle portfolio positions earlier than expected.
22 Mars 20213min
Special Episode: The Winding Road to Herd Immunity, Pt. 2
Chief Cross-Asset Strategist Andrew Sheets and Biotech equity analyst Matthew Harrison continue their conversation, with a focus on international progress for COVID-19 vaccinations.
19 Mars 20218min
Special Episode: The Winding Road to Herd Immunity
Chief Cross-Asset Strategist Andrew Sheets talks with Biotech equity analyst Matthew Harrison on dose availability, vaccine hesitancy and the timeline for herd immunity.
18 Mars 20219min
Michael Zezas: Three Revealing Numbers from the Stimulus Package
It may be hard for investors to conceptualize how substantial the impact of the American Rescue Plan Act may be, but three numbers provide perspective.
17 Mars 20212min
Chetan Ahya: Fed Tightening Could Come Sooner than Expected
With the rapid recovery of the U.S. economy, it is possible that inflation will overshoot the Fed’s tolerances by as early as mid-2022.
16 Mars 20214min
Mike Wilson: A Tougher Road Ahead for Small Caps?
After almost a year of extraordinary outperformance, could small caps could see more difficulties ahead as re-opening dynamics up the risk of cost pressures?
15 Mars 20213min
Andrew Sheets: A Complicated 2021 for Emerging Markets?
With global growth set to exceed expectations in 2021, emerging markets assets would appear set for outperformance. But this year, three factors cloud that narrative.
12 Mars 20212min
Special Episode: Markets and the Next Big Debate - Infrastructure
Conversations around the “Build Back Better” U.S. infrastructure plan are ramping up. What do investors need to know about its potential impact on markets?
11 Mars 20218min
